Targeting the PSGL-1 glycoprotein in cancer: cellular mechanisms and emerging immunotherapeutic strategies
Abstract Immune checkpoint immunotherapy has transformed contemporary oncology, establishing a new paradigm across diverse malignancies. P-selectin glycoprotein ligand-1 (PSGL-1; CD162) emerged as a new immunotherapeutic target. Initially characterized as a glycosylated selectin ligand controlling leukocyte rolling, ad...